Journal profile · Medicine-Oncology
Tumori Journal
ISSN 0300-8916 · eISSN 2038-2529 · Wichtig Publishing Srl · Italy
Tumori Journal: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.99; hybrid open access; APC about USD 4,150; 61 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Tumori Journal is published by Wichtig Publishing Srl and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology and Lung Cancer Treatments and Mutations, together about 19.6% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Tumori Journal is an international peer reviewed journal centred on cancer research and clinical practice in oncology, committed to providing autho...
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Giancarlo PruneriPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named Italy 31, Japan 4, United Kingdom 3, Switzerland 3, United States 2 (60 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology7.6%
- Cancer Treatment and PharmacologyMedicine6.4%
- Lung Cancer Treatments and MutationsMedicine5.7%
- Sarcoma Diagnosis and TreatmentMedicine5.7%
- Colorectal Cancer Treatments and StudiesMedicine5.2%
- Lymphoma Diagnosis and TreatmentMedicine4.9%
- Global Cancer Incidence and ScreeningMedicine4.5%
- Breast Lesions and CarcinomasMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.99LetPub ·
- Impact factor (publisher)
- 2Publisher website ·
- 5-year impact factor (publisher)
- 2.3Publisher website ·
- CiteScore 2026-06
- 4LetPub ·
- SJR 2026-06
- 0.57LetPub ·
- SNIP 2026-06
- 0.71LetPub ·
- h-index
- 75OpenAlex ·
- i10-index
- 2,381OpenAlex ·
- 2-year mean citedness
- 1.11OpenAlex ·
- Self-citation rate
- 5%LetPub ·
- Share of gold OA articles
- 24.79%LetPub ·
Volume
- Articles per year
- 46LetPub ·
Articles by year OpenAlex count · 8,317 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 69 | 22 | 12 |
| 2025 | 61 | 19 | 56 |
| 2024 | 63 | 23 | 146 |
| 2023 | 48 | 26 | 242 |
| 2022 | 62 | 21 | 555 |
| 2021 | 137 | 44 | 891 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,150 / GBP 3,043 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wichtig Publishing Srl
- Country or region
- Italy
- Language
- English
- ISSN
- 0300-8916
- Electronic ISSN
- 2038-2529
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Tumori Journal
What CAS zone is Tumori Journal in?
In the 2025 upgraded edition of the CAS Journal Ranking, Tumori Journal is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Tumori Journal?
The latest impact factor listed by LetPub is 1.99; CiteScore 4, h-index 75.
Where are the editorial board members of Tumori Journal based?
Of the 60 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are Italy (31), Japan (4) and United Kingdom (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Tumori Journal?
According to LetPub and DOAJ records, Tumori Journal is indexed in SCIE and Scopus.
Is Tumori Journal open access, and what is the APC?
Tumori Journal is a hybrid journal. For open-access publication: APC about USD 4,150.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .